NOVARTIS AG (NVS)

Expiry of Patent US7547719 for PROMACTA

The patent US7547719 for PROMACTA, an improved thrombopoietin mimetic developed by Novartis AG, is set to expire on July 13, 2025. The drug serves to stimulate platelet production and is of significant value in the treatment of conditions like thrombocytopenia. The expiration of this patent may impact Novartis financially as generic alternatives may enter the market, potentially reducing profits from PROMACTA.

Expiration of Patent US7265117 for QOLIANA

The patent for QOLIANA, US7265117, will expire on August 19, 2025. This expiration may enable generic competition for the product, which could impact revenue for QOLIANA's manufacturer. QOLIANA is associated with treating conditions addressed by the patented technology, which includes specific crystalline forms of a pharmaceutical compound. The patent's expiration may affect pricing and accessibility for patients requiring this treatment, though specific financial implications remain unclear.

Expiration of Patent US7559325 for TOBI PODHALER

The patent US7559325 for TOBI PODHALER, related to a device for inhaling aerosolized pharmaceutical formulations, will expire on October 27, 2025. This patent is held by Novartis AG and VIATRIS SPECIALTY LLC. The expiration may affect market competition for the TOBI PODHALER, a product designed for efficient delivery of medications for respiratory conditions, potentially leading to a decrease in revenues for Novartis as generic alternatives could enter the market.

Completion of MACUSTAR Clinical Trial - NCT03349801

The MACUSTAR clinical trial (NCT03349801) has been completed as of February 28, 2026. This trial focuses on assessing the efficacy of novel treatments aimed at improving outcomes for patients with age-related macular degeneration. Given the increasing prevalence of this condition among the elderly, successful outcomes could have significant implications both for patient quality of life and for associated healthcare costs.

Expiration of Patent US7893074 related to ZYKADIA

Patent US7893074 related to ZYKADIA, a novel pyrimidine derivative used as a pharmaceutical, assigned to Novartis AG and Novartis Pharmaceuticals Corp, is set to expire on April 25, 2026. The expiration of this patent may open the market for generic versions of ZYKADIA, potentially impacting Novartis's revenue from this product.

Expiration of Patent US8501760 for TASIGNA

Patent US8501760 for TASIGNA, a pharmaceutical composition containing nilotinib, assigned to Novartis AG and NOVARTIS PHARMACEUTICALS CORP, is set to expire on July 18, 2026. This expiration may open the market to generic versions of the drug, potentially impacting Novartis's revenue from this product as competition increases.

Patent US8389537 Expiry - TASIGNA

Patent US8389537 related to the drug TASIGNA will expire on July 18, 2026. TASIGNA, developed by Novartis AG and Novartis Pharmaceuticals Corp, is indicated for the treatment of certain forms of cancer. The expiration of this patent may lead to increased competition from generic versions, which could impact the financial performance of Novartis as market exclusivity ends.

Completion of National Register of Actionable Mutations Clinical Trial

The National Register of Actionable Mutations, a clinical trial sponsored by the Federation of Italian Cooperative Oncology Groups, is set to complete on October 27, 2026. This observational study aims to identify the frequency of actionable mutations in patients with advanced solid tumors through genetic-molecular characterization using high-throughput methods. Secondary objectives include assessing correlations between genetic alterations and various patient characteristics, as well as documenting clinical efficacy and toxicity data from targeted therapies based on these mutations. A total of 3,000 patients are expected to be enrolled, with data being collected from both retrospective medical records and prospective biological sample analysis. This trial is significant as it may enhance the understanding of molecular profiles in solid tumors, potentially influencing future treatments and clinical study designs.

• www.clinicaltrials.gov/study/NCT05918666

Expected Completion of RED4MS Clinical Trial for Treatment of Multiple Sclerosis

The RED4MS clinical trial, sponsored by Cellerys AG, aims to assess the safety and efficacy of peptide-coupled red blood cells in treating multiple sclerosis (MS). The trial comprises a phase Ib open-label dose-escalation study with nine patients and a phase IIa randomized study involving 45 patients. Expected completion is set for March 1, 2027. Enrollment for the trial has reached 135 participants. The strategic rationale behind this trial involves potentially advancing innovative MS treatment options.

• www.clinicaltrials.gov/study/NCT06430671

Expected Completion of DreaMS - Validation Study 1 Clinical Trial

The DreaMS - Validation Study 1 clinical trial, which is investigating digital biomarkers for Multiple Sclerosis (MS), is expected to complete on March 1, 2027. The trial, sponsored by the Research Center for Clinical Neuroimmunology and Neuroscience Basel, aims to validate the Healios+Me platform for continuous monitoring of MS patients using mobile device data. With an enrollment target of 300 participants, the study seeks to provide more accurate assessments of disease progression and improve individual therapeutic strategies. Currently, the trial is in a recruiting phase.

• www.clinicaltrials.gov/study/NCT05009160